Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Trial for the Safety and Efficacy of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Systemic Lupus Erythematosus

NCT05030779 is registered in ClinicalTrials.gov with Zhejiang University as lead sponsor.

NCT NCT05030779
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05030779 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Trial for the Safety and Efficacy of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Systemic Lupus Erythematosus
Lead sponsor
Zhejiang University
Phase
Phase 1
Overall status
Unknown status
Start date
September 10, 2021
Completion date
September 10, 2022
Enrollment
9 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune diseases, systemic lupus erythematosus